George Dunbar Joins Akadeum’s Board of Directors

Updated on Jan 4, 2020 Share

Akadeum Life Sciences has recently added George Dunbar to our Board of Directors.

George has spent his career as an executive and leader of numerous biotech companies. He most recently served as president and CEO of ISTO Biologics, a  private cell therapy and biologics company acquired by Thompson Street Capital in St. Louis, Missouri. Prior to ISTO, he was a Venture Partner with Arboretum Ventures, a leading life science venture capital firm.

Dunbar is joining Akadeum to work with the company on its current focused strategy of commercializing and growing its microbubble-based cell separation kits. “I’m excited to be joining Akadeum at a time when their initial products are being prepared for launch. The market has needed this type of radical simplification of next gen separation technologies,” said Dunbar.

Dunbar has served as CEO or Director for numerous public and private life science companies. In these roles, he has led several companies through their initial public offerings (IPOs) and acquisitions. He holds electrical engineering and M.B.A. degrees from Auburn University.

“George has incredible expertise in the life science industry in leading in the adoption of new technologies. Having George on the team is already making a big impact on our strategy and operations,” said Akadeum’s CEO, Brandon McNaughton.

Dunbar joins existing board directors: Doug Neal, Brock Siegel, John Younger, and Brandon McNaughton. He will be serving in place of Bill Wood, who served on the Akadeum board for over three years. We are very grateful to Bill Wood for his contribution to Akadeum. His guidance, stewardship, and time on the board were critical to our success.